Clinical trials: sponsored by Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
This is a study for patients with previously-treated advanced non-small cell lung cancer (NSCLC). The study will evaluate the safety of adding an investigational drug, MK-3475 to standard treatment with gemcitabine.
- Trial name
- NCT02422381
- Testing
- MK-3475, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Providence Health & Services
Hodgkin Lymphoma
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
The purpose of this study is to evaluate pembrolizumab (MK-3475) in the treatment of participants with relapsed or refractory Classical Hodgkin Lymphoma.
- Trial name
- NCT02684292
- Testing
- pembrolizumab, brentuximab vedotin
- Volunteers
- 304 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts.
- Trial name
- NCT06483334
- Testing
- Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab
- Where
- 25 sites in United States, Canada and 8 more
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma
A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) pembrolizumab (+) berahyaluronidase alfa in Japanese participants with recurrent or metastatic cutaneous squamous cell carcinoma…
- Trial name
- NCT06041802
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa
- Where
- 18 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Impairment
A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)
The goal of this study is to evaluate the effect of moderate and severe renal impairment (RI) on the pharmacokinetics (PK), safety, and tolerability of MK-8527. There will be no hypothesis testing in the study.
- Trial name
- NCT06295796
- Testing
- MK-8527
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer Metastatic, BRCA 1 Gene Mutation
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in…
- Conditions
- Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
- Trial name
- OlympiAD (NCT02000622)
- Testing
- Olaparib, Physician's choice chemotherapy
- Where
- 171 sites in United States, Bulgaria and 17 more
- Volunteers
- 302 people
- Sponsor
- AstraZeneca
Healthy, Renal Impairment
A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)
The goal of this study is to learn what happens to calderasib levels in a person's body over time. Researchers will measure what happens to calderasib levels in the body when it is given to people with moderate or severe renal…
- Trial name
- NCT06814119
- Testing
- Calderasib
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Adult
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Ref: Protocol Version 9.1 05 December 2024. NOUS-209-01 is a multicenter, open-label, multiple cohorts, clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of…
- Trial name
- NCT04041310
- Testing
- GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose
- Where
- 46 sites in United States, Belgium and 4 more
- Volunteers
- 115 people
- Sponsor
- Nouscom SRL
Vaccination
Can Stories Encourage the Elderly to Vaccinate? Combining Viewer-tailored Personal Narrative Videos With Informational Videos to Improve Vaccine Uptake Among Older Adults
This study will compare the use of informational videos only, personal story videos only, and the combination of both, to see which is most effective in increasing vaccination among older adults.
- Trial name
- NCT06890403
- Testing
- Informational Animation Video, Personal Narrative Video
- Where
- United States
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Sarcoma
Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Soft tissue sarcomas (STS) are a group of rare mesenchymal neoplasms affecting all ages. STS most commonly present as localised disease but despite surgery and adjuvant treatment more than half of patients will develop recurrent…
- Trial name
- GEMMK (NCT03123276)
- Testing
- Pembrolizumab, Gemcitabine
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Stage IV Non-small Cell Lung Cancer
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in patients with stage IV non-squamous…
- Trial name
- NCT03559049
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Ovarian Cancer Recurrent
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
This is a phase II single arm efficacy/safety trial that will evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP rintatolimod (TLR-3 agonist) and IV…
- Trial name
- NCT03734692
- Testing
- Rintatolimod, Pembrolizumab, Cisplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Robert Edwards
Healthy
A Study to Evaluate the Effect of Formulation and Food on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-011)
This study has 2 parts. Researchers want to learn what happens to calderasib in a healthy person's body over time in both parts.
- Trial name
- NCT06942741
- Testing
- Calderasib OCT, Calderasib FCT
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study of the Effect of Itraconazole and Phenytoin on Calderasib (MK-1084) in Healthy Adults (MK-1084-008)
The goal of this study is to learn what happens to calderasib in a healthy person's body over time, called a pharmacokinetic (PK) study.
- Trial name
- NCT06719557
- Testing
- Calderasib, Itraconazole, Phenytoin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Syncytial Virus Infection
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants.
- Trial name
- CLEVER (NCT04767373)
- Testing
- Clesrovimab
- Where
- 217 sites in United States, Argentina and 22 more
- Volunteers
- 3,632 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
End-Stage Renal Disease, End-Stage Kidney Disease
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an…
- Conditions
- End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
- Trial name
- NCT05027074
- Testing
- MK-2060
- Where
- 120 sites in United States, Argentina and 13 more
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)
The purpose of this study is to evaluate the effect of food, formulation, and a PPI on the levels of calderasib in a person's body over time.
- Trial name
- NCT06619314
- Testing
- Calderasib, PPI
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)
The goal of the study is to see what happens to levels of midazolam and digoxin in a person's body over time (a pharmacokinetic or PK study).
- Trial name
- NCT06575933
- Testing
- Calderasib, Midazolam, Digoxin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Financial Burden, Financial Toxicity
Proactive Costs of Care Study
The Proactive Costs of Care intervention is an educational intervention designed to help patients deal with the cost of cancer care.
- Conditions
- Financial Burden, Financial Toxicity, Financial Stress, Financial Navigation
- Trial name
- PCOC (NCT07217262)
- Testing
- Educational Intervention
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
The primary purpose of the study is to assess the pharmacokinetics (PK) profile of pembrolizumab following subcutaneous (SC) injection of pembrolizumab coformulated with hyaluronidase, and to evaluate the objective response rate…
- Conditions
- Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory
- Trial name
- NCT06504394
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa
- Where
- 29 sites in United States, Australia and 9 more
- Volunteers
- 66 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.